ARWR PE ratio history
How has ARWR's PE ratio performed in the past
The mean historical PE ratio of Arrowhead Pharmaceuticals over the last seven years is 145.59. Looking back at the last seven years, ARWR's PE ratio peaked in the Mar 2020 quarter at 287.7, with a price of $28.77 and an EPS of $0.1. The Sep 2019 quarter marked the lowest point at 39.14, with a price of $28.18 and an EPS of $0.72.
Today
N/A
Average
145.59
Median
115.33
Minimum
39.14
Maximum
287.7
Arrowhead Pharmaceuticals PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $19.37 | -$5 |
| 2023 | N/A | N/A | $26.87 | -$1.92 |
| 2022 | N/A | N/A | $33.05 | -$1.67 |
| 2021 | N/A | N/A | $62.43 | -$1.36 |
| 2020 | N/A | N/A | $43.06 | -$0.84 |
| 2019 | 39.14 | N/A | $28.18 | $0.72 |
| 2018 | N/A | N/A | $19.17 | -$0.65 |
ARWR average PE ratio chart
What is the average PE ratio of ARWR for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
145.59
15-year avg
N/A
ARWR PE vs peers
What is ARWR's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 17.21 | $375.13B |
| ALNY Alnylam Pharmaceuticals Inc | N/A | $33.3B |
| INO Inovio Pharmaceuticals Inc | N/A | $70.03M |
| LGND Ligand Pharmaceuticals Inc | N/A | $2.14B |
| MRNA Moderna Inc | N/A | $10.73B |
| ARWR Arrowhead Pharmaceuticals Inc | N/A | $1.7B |
Frequently asked questions
What is Arrowhead Pharmaceuticals's PE ratio?
The current price to earnings ratio of ARWR cannot be determined, as its EPS of -$5.16 is negative.
What is the highest PE ratio for ARWR?
The highest quarterly PE ratio in the last seven years has been 287.7 and it was in the Mar 2020 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.